TY - JOUR T1 - Cyclin-dependent kinase 2 (Cdk2) controls phosphatase-regulated signaling and function in platelets JF - bioRxiv DO - 10.1101/2020.05.31.126953 SP - 2020.05.31.126953 AU - Paul R. Woods, Jr. AU - Brian L. Hood AU - Sruti Shiva AU - Thomas P. Conrads AU - Sarah Suchko AU - Richard Steinman Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/06/28/2020.05.31.126953.abstract N2 - Cell cycle regulatory molecules including cyclin-dependent kinases can be recruited into non-nuclear pathways to coordinate cell cycling with the energetic state of the cell or with functions such as motility. Little is known about the role of cell cycle regulators in anucleate cells such as platelets. We report that cyclin-dependent kinase (cdk2) is robustly expressed in human platelets, is activated by thrombin and is required for platelet activation. Cdk2 activation required Src signaling downstream of the platelet thrombin receptor PAR1. Kinase-active cdk2 promoted the activation of downstream platelet kinases by phosphorylating and inactivating the catalytic subunit of protein phosphatase 1 (PP1). Erk was bound to PP1 in a complex with the PP1 regulator PPP1R12a (MYPT1) in platelets, and cdk2 inhibited the phosphatase activity of PP1 and PPP1R12a bound complexes. The requirement for cdk2 in Erk activation could be replaced by the phosphatase inhibitor calyculin if cdk2 was inhibited. Blockade of cdk2 kinase with chemical and peptide cdk2 inhibitors resulted in suppression of thrombin-induced platelet aggregation, and partially inhibited GPIIb/IIIa integrin activation as well as platelet secretion of P-Selectin and ATP. Together, these data indicate a requirement for cdk2 in platelet activation.Competing Interest StatementThe authors have declared no competing interest. ER -